Investigating how the chemical structure of LEQVIO affects its effectiveness
Official title: Comprehensive assessment of the diastereomer composition of LEQVIO (Inclisiran) to determine how chemical synthesis impacts biological activity
Funded at University of Maryland Baltimore · NIH-11062225 · Data updated 2026-11-12
This study is looking at how different versions of the cholesterol-lowering medication LEQVIO work in the body, to find out which ones are the most effective for helping patients lower their cholesterol better.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $299,975 |
| NIH project number | 1U01FD008322-01 |
| Project ID | NIH-11062225 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who are prescribed LEQVIO for cholesterol management.
✕Less likely to help
Patients who are not using LEQVIO or those with conditions unrelated to cholesterol management may not benefit from this research.
What this research studies
This research focuses on understanding the different chemical forms of LEQVIO (Inclisiran), a medication used to lower cholesterol. It examines how the specific chemical modifications made during its production can influence its biological activity and effectiveness in treating patients. By analyzing the diastereomer composition of LEQVIO, the study aims to identify which forms are most beneficial for patient outcomes. This could lead to improved dosing strategies and enhanced therapeutic efficacy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients requiring cholesterol management.
How similar studies have gone: While the approach of analyzing diastereomer compositions is relatively novel, similar studies in the field of oligonucleotide therapeutics have shown promise in enhancing drug efficacy.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Jones, Jace W — University of Maryland Baltimore
- Study coordinator: Jones, Jace W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.